NCT03916094 2022-05-05Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2Shanghai Henlius BiotechPhase 1 Completed11 enrolled
NCT02593708 2017-11-17Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+University of California, San FranciscoPhase 1 Terminated6 enrolled